Can cost-effectiveness principles be ignored in urgent times?

Zoltán Kaló,Bertalan Németh,Antal Zemplényi

doi:10.2217/cer-2021-0211

Abstract

Can cost-effectiveness principles be ignored in urgent times?

Highlights

Managing uncertainty in health technology assessment As part of the health policy tools, health technology assessment (HTA) is most commonly used to judge the clinical and economic value of new technologies or existing technologies in new indications in order to support pricing and reimbursement decisions
During the last decades public reports by prestigious HTA bodies are more and more regularly referenced in many different countries and publications; it can be concluded that mandatory HTA requirement across jurisdictions has improved the evidence base of new health technologies globally
Pandemic periods – a special case of uncertainty Pandemic situations are special, as waiting for better evidence base to judge the true value of potentially beneficial technologies put risk on the spread of infections, which can have detrimental implications on the health of infected patients

Summary

Introduction

Managing uncertainty in health technology assessment As part of the health policy tools, health technology assessment (HTA) is most commonly used to judge the clinical and economic value of new technologies or existing technologies in new indications in order to support pricing and reimbursement decisions. Pandemic periods – a special case of uncertainty Pandemic situations (for example: SARS, Ebola and COVID-19) are special, as waiting for better evidence base to judge the true value of potentially beneficial technologies put risk on the spread of infections, which can have detrimental implications on the health of infected patients.

Results

Conclusion